A categorical structure–activity relationship analysis of GPR119 ligands

References

• N.G. Morgan and S. Dhayal, The significance of GPR119 agonists as a future treatment for type 2 diabetes, Drug News Perspect. 23 (2010), pp. 418–424.
   PubMed Web of Science ®Google Scholar
• H.A. Overton, M. Fyfe, and C. Reynet, GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity, Br. J. Pharmacol. 153 Suppl 1 (2008), pp. S76–81.
   PubMed Web of Science ®Google Scholar
• R.M. Jones, J.N. Leonard, D.J. Buzard, and J. Lehmann, GPR119 agonists for the treatment of type 2 diabetes, Expert Opin. Ther. Pat. 19 (2009), pp. 1339–1359.
   PubMed Web of Science ®Google Scholar
• U. Shah and T.J. Kowalski, GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders, Vitam. Horm. 84 (2010), pp. 415–448.
   PubMed Web of Science ®Google Scholar
• Z. Chu, R.M. Jones, H. He, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao, H. Mondala, D. Bagnol, D. Unett, Y. Liang, K. Demarest, G. Semple, D.P. Behan, and J. Leonard, A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release, Endocrinology 148 (2007), pp. 2601–2609.
   PubMed Web of Science ®Google Scholar
• G. Flock, D. Holland, Y. Seino, and D.J. Drucker, GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms, Endocrinology 152 (2011), pp. 374–383.
   PubMed Web of Science ®Google Scholar
• L. Lauffer, R. Iakoubov, and P.L. Brubaker, GPR119: “Double-dipping” for better glycemic control, Endocrinology 149 (2007), pp. 2035–2037.
   Web of Science ®Google Scholar
• L. Baggio and D.J. Drucker, Biology of incretins: GLP-1 and GIP, Gastroenterology 132 (2007), pp. 2131–2157.
   PubMed Web of Science ®Google Scholar
• J.W. Polli, E. Hussey, M. Bush, G. Generaux, G. Smith, D. Collins, S. McMullen, N. Turner, and D.J. Nunez, Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: From in vitro data to clinical study design, Xenobiotica 43 (2013), pp. 498–508.
   PubMed Web of Science ®Google Scholar
• L.B. Katz, J.J. Gambale, P.L. Rothenberg, S.R. Vanapalli, N. Vaccaro, L. Xi, T.C. Sarich, and P.P. Stein, Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes, Diabetes Obs. Metab. 14 (2012), pp. 709–716.
   PubMed Web of Science ®Google Scholar
• D.J. Nunez, M.A. Bush, D.A. Collins, S.L. McMullen, D. Gillmor, G. Apseloff, G. Atiee, L. Corsino, L. Morrow, and P.L. Feldman, Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: Results from two randomized studies, PloS one 9 (2014), pp. e92494.
   PubMed Web of Science ®Google Scholar
• L.B. Katz, J.J. Gambale, P.L. Rothenberg, S.R. Vanapalli, N. Vaccaro, L. Xi, D.C. Polidori, E. Vets, T.C. Sarich, and P.P. Stein, Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects, Clin. Pharmacol. Therap. 90 (2011), pp. 685–692.
   PubMed Web of Science ®Google Scholar
• A.R. Cunningham, S.L. Cunningham, D.M. Consoer, S.T. Moss, and M.H. Karol, Development of an information-intensive structure-activity relationship model and its application to human respiratory chemical sensitizers, SAR QSAR Environ. Res. 16 (2005), pp. 273–285.
   PubMed Web of Science ®Google Scholar
• A.R. Cunningham, S.T. Moss, S.A. Iype, G. Qian, S. Qamar, and S.L. Cunningham, Structure-activity relationship analysis of rat mammary carcinogens, Chem. Res. Toxicol. 21 (2008), pp. 1970–1982.
   PubMed Web of Science ®Google Scholar
• A.K. Saxena and K.K. Roy, Hierarchical virtual screening: Identification of potential high-affinity and selective beta(3)-adrenergic receptor agonists, SAR QSAR Environ. Res. 23 (2012), pp. 389–407.
   PubMed Web of Science ®Google Scholar
• P. Kumar, A. Kumar, and Z.H. Song, Structure-activity relationships of fatty acid amide ligands in activating and desensitizing G protein-coupled receptor 119, Eur. J. Pharmacol. 723 (2014), pp. 465–472.
   PubMed Web of Science ®Google Scholar
• A.R. Cunningham, C.A. Carrasquer, and D.R. Mattison, A categorical structure-activity relationship analysis of the developmental toxicity of antithyroid drugs, Int. J. Pediatr. Endocrinol. 2009 (2009), 936154.
   Google Scholar
• S. Qamar, C.A. Carrasquer, S.L. Cunningham, and A.R. Cunningham, Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines, Anticancer Res. 31 (2011), pp. 247–522.
   Google Scholar
• R.M. Jones and J.N. Leonard, The emergence of GPR119 agonists as anti-diabetic agents, Ann. Rep. Med. Chem. 44 (2009), pp. 149–170.
   Web of Science ®Google Scholar
• G. Semple, B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, V. Dave, W. Thomsen, D.J. Unett, C. Xing, S. Bossie, C. Carroll, Z. Chu, A.J. Grottick, E.K. Hauser, J. Leonard and R.M. Jones, Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119, J. Med. Chem. 51 (2008), pp. 5172–5175.
   PubMed Web of Science ®Google Scholar
• H.A. Overton, A.J. Babbs, S.M. Doel, M.C. Fyfe, L.S. Gardner, G. Griffin, H.C. Jackson, M.J. Procter, C.M. Rasamison, M. Tang-Christensen, P.S. Widdowson, G.M. Williams, and C. Reynet, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents, Cell. Metab. 3 (2006), pp. 167–175.
   PubMed Web of Science ®Google Scholar
• Y. Wu, J.D. Kuntz, A.J. Carpenter, J. Fang, H.R. Sauls, D.J. Gomez, C. Ammala, Y. Xu, S. Hart, and S. Tadepalli, 2,5-Disubstituted pyridines as potent GPR119 agonists, Bioorg. Med. Chem. Lett. 20 (2010), pp. 2577–2581.
   PubMed Web of Science ®Google Scholar
• M. Sakairi, M. Kogami, M. Torii, H. Kataoka, H. Fujieda, M. Makino, D. Kataoka, R. Okamoto, T. Miyazawa, M. Okabe, M. Inoue, N. Takahashi, S. Harada, and N. Watanabe, Synthesis and SAR studies of bicyclic amine series GPR119 agonists, Bioorg. Med. Chem. Lett. 22 (2012), pp. 5123–5128.
   PubMed Web of Science ®Google Scholar
• X. Zhu, D. Huang, X. Lan, C. Tang, Y. Zhu, J. Han, W. Huang, and H. Qian, The first pharmacophore model for potent G protein-coupled receptor 119 agonist, Eur. J. Med. Chem. 46 (2011), pp. 2901–2907.
   Google Scholar
• B. Wellenzohn, U. Lessel, A. Beller, T. Isambert, C. Hoenke, and B. Nosse, Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry, J. Med. Chem. 55 (2012), pp. 11031–11041.
   PubMed Web of Science ®Google Scholar